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Over the last decade an increasing number of studies have focused on the ability
of G protein-coupled receptors to form heteromers and explored how receptor
heteromerization modulates the binding, signaling and trafficking properties of individual
receptors. Most of these studies were carried out in heterologous cells expressing epitope
tagged receptors. Very little information is available about the in vivo physiological role of
G protein-coupled receptor heteromers due to a lack of tools to detect their presence in
endogenous tissue. Recent advances such as the generation of mouse models expressing
fluorescently labeled receptors, of TAT based peptides that can disrupt a given heteromer
pair, or of heteromer-selective antibodies that recognize the heteromer in endogenous
tissue have begun to elucidate the physiological and pathological roles of receptor
heteromers. In this review we have focused on heteromer-selective antibodies and
describe how a subtractive immunization strategy can be successfully used to generate
antibodies that selectively recognize a desired heteromer pair. We also describe the
uses of these antibodies to detect the presence of heteromers, to study their properties
in endogenous tissues, and to monitor changes in heteromer levels under pathological
conditions. Together, these findings suggest that G protein-coupled receptor heteromers
represent unique targets for the development of drugs with reduced side-effects.
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INTRODUCTION
Since the first report showing that metabotropic GABAB recep-
tors, members of the family C of G protein-coupled receptors
(GPCRs), form constitutive heteromers (White et al., 1998; Kuner
et al., 1999; Pin et al., 2009) an increasing number of studies
have provided evidence suggesting that other GPCRs, particu-
larly those belonging to family A, also heteromerize (Albizu et al.,
2010; Gomes et al., 2013a; Hiller et al., 2013; Szafran et al., 2013).
However, most of the studies reporting GPCR heteromerization
were carried out in heterologous cells co-expressing differentially
epitope tagged recombinant receptors. Concerns that heteromer-
ization in heterologous cells could be due to over-expression
of individual receptors and that the unique signaling reported
for a given heteromer is due to receptor cross-talk via down-
stream signaling rather than direct receptor-receptor interactions
led investigators in the field to propose a set of criteria to be ful-
filled in order to consider that a GPCR pair forms an heteromer
in endogenous tissue (Ferre et al., 2009): (i) both receptors can
be detected in the same subcellular compartment in a cell; (ii)
close proximity between the two receptors for direct interactions
can be demonstrated through the use of either proximity ligation
assays, ligand-based FRET, or heteromer-selective probes such as
antibodies only in wild-type tissue; (iii) the receptors can be co-
immunoprecipitated from wild-type but not from tissue lacking
one of the receptors; (iv) the heteromer pair exhibits a “bio-
chemical fingerprint” in wild-type tissue that matches that seen
in heterologous cells co-expressing both receptors but not cells
expressing only one of the receptors; and (v) heteromer formation
can be disrupted by agents such as TAT peptides and this leads to
alterations in the “biochemical fingerprint” to one that resembles
that of individual receptor protomers (Ferre et al., 2009).
In order to detect and map the presence of a GPCR heteromer
in endogenous tissue, sensitive and selective tools are needed.
Such tools could help not only to monitor heteromer levels under
physiological and pathological conditions but also to tease apart
the contribution of receptor homomers and heteromers to a
given physiological response. In order to address this need our
laboratory undertook the challenge to generate monoclonal anti-
bodies that selectively recognize a given heteromer pair. Since
monoclonal antibodies recognize a single epitope and are highly
specific, they would not only facilitate detection of the targeted
heteromer in endogenous tissue but would also permit studies to
elucidate the contribution of the heteromer to signaling in tis-
sues/membranes expressing both receptors. In general it is easy
to generate antibodies to immunodominant and abundant epi-
topes; however this task is more challenging when using epitopes
that are likely to be rare or less immunodominant. This would be
the case with “heteromer-selective” epitopes where very little is
known about the “heteromer” interface. We therefore decided to
use a subtractive immunization strategy to improve our changes
of raising such antibodies. This strategy has been successfully used
in the cancer field to generate monoclonal antibodies that can
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specifically block metastasis but not proliferation of cancer cells
(Brooks et al., 1993), antibodies that can discriminate proteins
that have a similar sequence (Sleister and Rao, 2002), or anti-
bodies that could be used as diagnostic tools in certain types of
cancer (Trefzer et al., 2000; Yasumoto et al., 2012). In this review
we describe the strategy used to generate and characterize anti-
bodies selective to either μOR-δOR, δOR-κOR, δOR-CB1R, and
AT1R-CB1R heteromers (Table 1).
GENERATION OF HETEROMER-SELECTIVE ANTIBODIES
USING A SUBTRACTIVE IMMUNIZATION STRATEGY
An important requirement to generate antibodies that can selec-
tively recognize a given GPCR heteromer is the immunogen. An
ideal immunogen would be a synthetic peptide that mimics the
heteromeric region between two GPCRs since the latter would
be distinct and unique compared to the homomeric regions.
However, not much is known about the heteromer interface or
a unique region shared by heteromers. Hence we used mem-
branes from cells expressing the heteromer pair of interest as the
immunogen. Given the likelihood that the heteromeric epitopes
would be of very low abundance and of low immunogenicity,
thereby preventing their detection by antibody producing cells,
direct immunization with such membranes would have a low
probability of successfully generating heteromer-selective anti-
bodies. Therefore in order to improve our chances of generating
heteromer-selective antibodies we used a subtractive immuniza-
tion strategy (Salata et al., 1992; Sleister and Rao, 2001, 2002)
that involves twomajor steps: (i) tolerization of mice to unwanted
epitopes, and (ii) immunization with membranes expressing the
heteromer pair of interest. Tolerization to unwanted epitopes can
be achieved by immunizing mice with an emulsion of membranes
from cells used to express the heteromer pair in combination with
complete Freund’s adjuvant (Gomes et al., 2013b); these cells can
be CHO or HEK-293 cells that are usually used in GPCR co-
expression studies as well as cells that endogenously express one of
the receptor protomers (Gomes et al., 2013b). The mice are then
treated for the next 3 days with cyclophosphamide to kill acti-
vated antibody producing cells (Gomes et al., 2013b). Every 15
days mice are administered with booster injections comprised of
membrane emulsions in Freund’s incomplete adjuvant followed
by the 3 day treatment with cyclophosphamide (Gomes et al.,
2013b). Booster injections are repeated until a consistently low
titer is observed by ELISA with the membranes used for the toler-
ization step (Gomes et al., 2013b). Once animals are tolerized they
are immunized with membranes expressing the heteromer pair
of interest (Gomes et al., 2013b). Booster injections are repeated
until a high titer is obtained by ELISA (using membranes that co-
express both receptors). Animals are killed and individual spleens
used to generate monoclonal antibodies using standard protocols
(Gomes et al., 2013b). Once monoclonal antibodies are obtained,
individual clones are tested for heteromer selectivity by ELISA,
immunofluorescence or Western blot analysis using (i) cells that
express individual receptors; (ii) cells that co-express both of the
protomers of interest; (iii) cells that co-express one of the recep-
tor protomers with a different partner GPCR; and (iv) tissues
from wild-type and from animals lacking each of the receptor
protomers (Gomes et al., 2013b). An antibody is considered to
be heteromer-selective only if it gives a signal with cells or tissues
co-expressing both of the protomers of interest. It is to be noted
that heteromer selectivity may be observed with one screening
procedure such as ELISA but not with another such as Western
blotting or immunofluorescence since either heat denaturation
of membrane proteins (as in the case of Western blot analysis)
and/or tissue fixation (in the case of immunofluorescence stud-
ies) could mask the epitope identified by the antibody. Thus one
needs to be careful about selecting the screening technique to
allow for detection of the antigen under the assay of choice. Using
this subtractive immunization strategy we successfully generated
antibodies selective for either μOR-δOR, δOR-κOR, δOR-CB1R,
or AT1R-CB1R heteromers (Gupta et al., 2010; Rozenfeld et al.,
2011; Berg et al., 2012; Bushlin et al., 2012). In the following sec-
tions we describe these heteromer pairs and the studies carried
out using heteromer selective antibodies.
μOR-δOR HETEROMERIZATION
A number of early studies proposed heteromerization between
μOR and δOR based on interactions between these receptors. For
example, pharmacological studies showed that morphine (a μOR
agonist) shifted competitive radiolabeled leucine-enkephalin
displacement curves by unlabeled leucine-enkephalin (a δOR
agonist) into non-competitive curves (Rothman and Westfall,
1982). In addition behavioral studies showed that δOR agonists
(endogenous peptides or synthetic agonists) could potentiate
μOR-mediated antinociception while potent δOR antagonists
attenuated not only morphine-mediated antinociception but also
the development of tolerance to this drug (reviewed in Fujita
et al., 2014a). Furthermore studies showed that chronic treat-
ment withmorphine increases surface expression of δOR in either
cultured cortical or dorsal root ganglion neurons and in the dor-
sal horn of the spinal cord of wild-type but not in mice lacking
μOR (Cahill et al., 2001; Morinville et al., 2003; Gendron et al.,
2006). Studies with animals lacking either μOR or δOR further
support interactions between these receptors. These studies indi-
cate that δOR-mediated antinociception requires the presence
of functional μOR (Matthes et al., 1996, 1998) and that δOR
contributes to the development of tolerance to morphine (Zhu
et al., 1999). The latter observation is also supported by stud-
ies using antisense oligonucleotides to decrease δOR expression
in the brain (Sanchez-Blazquez et al., 1997). In addition, it has
been reported that treatment with a selective δOR antagonist, nal-
triben, reduces the rewarding effects of morphine as measured
using the morphine conditioned place preference test and this
is accompanied by increases in δOR levels at the post-synaptic
density fraction (Billa et al., 2010). Taken together these studies
suggested receptor-receptor interactions between μOR and δOR.
A major requirement for two receptors to directly interact
with each other is that they be localized not only to the same
cell but also to the same subcellular compartment. Early evi-
dence for the presence of μOR and δOR in the same cell came
from electrophysiological and radiolabeled binding studies using
either neurons or neuroblastoma cell lines (Egan andNorth, 1981;
Zieglgansberger et al., 1982; Yu et al., 1986; Kazmi and Mishra,
1987; Baumhaker et al., 1993; Palazzi et al., 1996). In addition,
a number of immunohistochemical studies showed that both
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receptors were present in the same subcellular compartment in
the brain and spinal cord by using receptor-selective antibod-
ies (Arvidsson et al., 1995; Cheng et al., 1997; Wang and Pickel,
2001). Controversy arose about the co-localization of μOR and
δOR in the dorsal root ganglions of the spinal cord primar-
ily due to data with mice with a knockin of eGFP-tagged δOR
that showed that both receptors were segregated from each other
(<5% neurons showed receptor colocalization) with μOR being
expressed in small peptidergic neurons where it was involved
in inhibition of pain induced by noxious heat while δOR was
expressed in medium-sized non-peptidergic and large myelinated
neurons where it was involved in inhibition of pain induced by
mechanical stimuli (Scherrer et al., 2009). However, previous and
recent observations questioned the lack of μOR and δOR colo-
calization. For example, support for colocalization came from
(i) studies using either immunogold electron microscopy (Cheng
et al., 1997), single-cell PCR, in situ hybridization or immunos-
taining to demonstrate the presence of μOR and δOR in small
peptidergic DRG neurons (Wang et al., 2010); (ii) studies show-
ing that myc-tagged δOR is present in CGRP-containing large
dense core vesicles while eGFP-tagged δOR is present at the cell
surface when expressed in small DRGs (Zhang and Bao, 2012)
suggesting that the C-terminal GFP might affect receptor traf-
ficking; (iii) studies treating peptidergic nociceptors expressing
μOR and δOR with selective agonists that prevent substance
P release induced by formalin or capsaicin treatment and this
could be blocked by receptor selective antagonists (Beaudry et al.,
2011); (iv) studies using electrophysiological recordings from a
wide range of neurons in the spinal trigeminal nucleus of anes-
thetized animals showing that activation of either μOR or δOR
relieves both thermal- or mechanical induced pain with same
potency (Normandin et al., 2013); and (v) studies showing co-
localization of μOR and δOR in the plasma membrane of a small
population of CGRP-containing neurons in eGFP-tagged δOR
knockin mice (Bardoni et al., 2014). Additional support for co-
localization comes from mice expressing eGFP-tagged δOR and
mCherry-tagged μOR. These mice show that ∼40% of eGFP-
tagged δOR positive and ∼30% of mCherry-tagged μOR positive
DRGs co-express the two receptors (Erbs et al., 2014). In addition,
these mice show colocalization of μOR and δOR in neurocir-
cuits involved in survival, pain regulation, as well as food intake,
water consumption and sexual behavior (Erbs et al., 2014). In the
hippocampus co-expression of eGFP-tagged δOR and mCherry-
tagged μOR is detected in GABAergic interneurons and for-
mation of μOR-δOR interacting complexes was demonstrated
by co-immunoprecipitation studies (Erbs et al., 2014). Taken
together these results demonstrate substantial co-localization of
μOR or δOR in the brain and spinal cord.
In order to detect the presence of μOR-δOR heteromers in
endogenous tissue our laboratory generated heteromer-selective
antibodies (Table 1) using a subtractive immunization strategy
(Gupta et al., 2010). ELISA with these antibodies show that
they detect an epitope present only in cells co-expressing μOR
and δOR and not in cells expressing individual receptors or
co-expressing either μOR or δOR in combination with other
GPCRs (Gupta et al., 2010). Moreover, the signal obtained in
ELISA is reduced when the antibodies are pre-incubated with
membranes co-expressing μOR and δOR but not with mem-
branes expressing individual receptors (Gupta et al., 2010). In
addition, these antibodies recognize an epitope present only in
membranes fromwild-typemice but not frommice lacking either
μOR or δOR (Gupta et al., 2010). Furthermore, the heteromer-
selective antibodies showed better recognition of co-expressed
wild-type receptors compared to co-expressed chimeric receptors
where regions of μOR were substituted with δOR and vice-versa
(Gupta et al., 2010). Taken together these results indicate that the
antibodies selectively recognize the μOR-δOR heteromer.
The μOR-δOR heteromer-selective antibodies can be used for
immunohistochemical studies to detect the presence of these het-
eromers in endogenous tissue or primary DRG cultures (Gupta
et al., 2010). An interesting finding with these antibodies is that
chronic treatment with escalating doses of morphine under con-
ditions that lead to the development of antinociceptive tolerance
leads to an increase in μOR-δOR heteromers in select brain
regions from wild-type but not from mice lacking either μOR
or δOR (Gupta et al., 2010). These regions include the medial
nucleus of the trapezoid body (MNTB), an auditory relay nucleus
and the rostral ventral medulla (RVM), a key relay nucleus
involved in pain perception (Gupta et al., 2010). Similar increases
in μOR-δOR heteromers were also observed in the cell bodies
and dendrites of primary DRG neurons following 48 h treatment
with morphine (Figure 1). More recently μOR-δOR heteromer-
selective antibodies were used to detect the presence of these
heteromers in ileal tissue (Fujita et al., 2014b).
Another criteria that a μOR and δOR heteromer has to fulfill
is that both receptor protomers have to be in close enough prox-
imity to directly interact. Co-immunoprecipitation studies using
either antibodies to epitope tags or to endogenous receptors show
thatμOR and δOR form interacting complexes only in spinal cord
membranes from wild-type (but not frommice lacking one of the
receptors) as well as in cells co-expressing both receptors (George
et al., 2000; Gomes et al., 2000, 2004). In addition we find that
the μOR-δOR heteromer-selective antibodies can immunopre-
cipitate the heteromer from primary dorsal root ganglion (DRG)
neurons as well as from cells co-expressing both receptors (Gupta
et al., 2010). That μOR and δOR are in close proximity to directly
interact was further supported by proximity based assays showing
that the two receptors are <100Å in live cells co-expressing both
receptors (Gomes et al., 2004; Hasbi et al., 2007).
A third criteria that the μOR-δOR heteromer has to fulfill is
that it exhibits a unique “biochemical fingerprint” that is seen
only in cells/tissues expressing both receptors. The “biochemi-
cal fingerprint” for μOR-δOR heteromers consists of changes in
ligand binding and signaling properties. These include (i) the
binding affinity of selective synthetic agonists is decreased while
that of endogenous peptidic agonists is increased (George et al.,
2000); (ii) occupancy of a receptor protomer allosterically mod-
ulates the binding and signaling profile of the partner protomer
(Gomes et al., 2000, 2004, 2011); (iii) the μOR-δOR heteromer
signals via either pertussis toxin insensitive Gαz (George et al.,
2000; Fan et al., 2005; Hasbi et al., 2007), pertussis toxin sensitive
Ca+2 signaling (Charles et al., 2003), or β-arrestin2 (Rozenfeld
and Devi, 2007) compared to individual receptor homomers that
signal via pertussis sensitive Gαi. A related point supporting
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FIGURE 1 | Detection of μOR-δOR heteromers in primary dorsal root
ganglion neurons using heteromer-selective antibodies. (A–D) Primary
dorsal root ganglion neurons (DRGs) from embryonic rats were treated
without (A,C) or with 10μM morphine (B,D) for 48 h. μOR-δOR heteromers
were visualized in the cell bodies (A,B) or in dendrites (B,D) using
heteromer-selective antibodies (red). (E,F) Primary DRGs from adult rats
were treated without (E) or with 10μM morphine (F) for 48 h and μOR-δOR
heteromers visualized using heteromer-selective antibodies (red). Morphine
treatment increases μOR-δOR heteromer levels. Blue color represents
nuclear DAPI staining.
receptor-receptor interactions is changes in maturation, endo-
cytosis and degradation. For example, a study showed that co-
expression of μOR and δOR leads to retention of the heteromer
in the Golgi and that increased cell surface expression of μOR-
δOR heteromers requires the expression of a chaperone protein,
receptor transport protein-4 (Decaillot et al., 2008). Moreover,
the presence of receptor transport protein-4 protects the μOR-
δOR heteromer from ubiquitination and degradation (Decaillot
et al., 2008). Another study showed that morphine and the opi-
oid antagonists naltrexone and naltriben could serve as chemical
chaperones that increase the cell surface expression of μOR-δOR
heteromers (Gupta et al., 2010). With regards to heteromer inter-
nalization one study used cells that expressed μOR and where
δOR expression was induced by treatment with ponasterone A
treatment to show that the receptor protomers internalized inde-
pendently from each other (Law et al., 2005). However, other
studies showed that treatment with some μOR or δOR agonists
(DAMGO, methadone, Deltorphin II, SNC80) but not others
(morphine, DPDPE, DSLET) could induce μOR-δOR heteromer
internalization (Hasbi et al., 2007; He et al., 2011; Milan-Lobo
and Whistler, 2011). Interestingly, internalized heteromers are
degraded (He et al., 2011; Milan-Lobo and Whistler, 2011) while
internalized receptor homomers are recycled to the cell surface
(Milan-Lobo and Whistler, 2011). Taken together these stud-
ies indicate that μOR-δOR heteromers exhibit unique properties
compared to individual receptor homomers.
A final and important criteria for a μOR-δOR heteromer is
the development of unique reagents that selectively target or dis-
rupt the biochemical fingerprint of the heteromer. Several such
reagents have been generated including (i) TAT fused peptides
that disrupt μOR-δOR heteromerization in vitro as well as in vivo
(He et al., 2011; Kabli et al., 2014); (ii) bivalent ligands that
are more potent than morphine and without significant devel-
opment of tolerance and dependence (Daniels et al., 2005); (iii)
heteromer-selective antibodies that block μOR-δOR heteromer-
mediated signaling (Gupta et al., 2010); and (iv) a small molecule
μOR-δOR biased agonist, CYM51050, that is as potent as mor-
phine but with lower development of tolerance (Gomes et al.,
2013c). In the case of TAT fused peptides, a peptide fused to
the transmembrane domain 1 of μOR disrupted the formation
of μOR-δOR heteromers both in heterologous cells and in the
spinal cord (He et al., 2011). Disruption of μOR-δOR heteromers
in the spinal cord, in turn, led to an increase in morphine-
mediated analgesia (He et al., 2011). Another peptide that could
disrupt the formation of μOR-δOR heteromers in heterologous
cells comprised of a TAT peptide fused to a sequence correspond-
ing to the distal carboxyl terminal tail of δOR (Kabli et al., 2014).
Interestingly, intra-accumbens administration of this TAT pep-
tide attenuated the antidepressant and antianxiolytic effects of the
δOR agonist UFP-512 (Kabli et al., 2014). In the case of bivalent
ligands a compound comprising a δOR antagonist that is sep-
arated from a μOR agonist by a 21-atom spacer arm has been
synthesized and named MDAN21 (Daniels et al., 2005). Studies
show that MDAN21-mediated antinociception is 100 times more
potent than that of morphine and that chronic administration of
this compound does not lead to the development of tolerance and
dependence (Daniels et al., 2005). In addition, MDAN21 prevents
the internalization of μOR-δOR heteromers probably by occupy-
ing both protomers and immobilizing the heteromer at the cell
surface (Yekkirala et al., 2013). Other bivalent ligands consist-
ing of high-affinity μOR ligands (oxymorphone or naltrexone)
linked by a spacer arm to low-affinity δOR ligands (ENTI or DM-
SNC80 respectively) have also been synthesized (Harvey et al.,
2012); however not much is known about the analgesic effects
of these ligands and whether their administration leads to side-
effects. In the case of monoclonal μOR-δOR heteromer-selective
antibodies studies show that they can block the ability of low con-
centrations of a δOR selective antagonist, TIPPψ, to potentiate
the binding and signaling by DAMGO, a selective μOR agonist
(Gupta et al., 2010). More recently, a small molecule μOR-δOR
biased agonist, CYM51050, was identified by high-throughput
screening of a small molecule library using a β-arrestin recruit-
ment assay (Gomes et al., 2013c). Studies with CYM51010 show
that it is more efficacious at activating G-proteins and recruiting
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β-arrestin in cells expressing the μOR-δOR heteromer compared
to cells expressing either μOR or δOR homomers (Gomes
et al., 2013c). In addition, while the antinociceptive activity of
CYM51010 is similar to that of morphine, chronic administration
of this biased agonist results in lower antinociceptive tolerance
compared to morphine (Gomes et al., 2013c). That the signaling
and antinociceptive effects of CYM51010 are mostly mediated via
μOR-δOR heteromers is supported by the observation that they
can be partly but significantly blocked by μOR-δOR heteromer-
selective antibodies (Gomes et al., 2013c). Taken together, these
unique heteromer targeting reagents show that μOR-δOR het-
eromers occur in vivo and that the heteromer-selective antibodies
are useful not only in detecting the presence of an heteromer
in endogenous tissue under normal and pathological conditions
but also to study the properties of the heteromers and to identify
heteromer selective ligands.
κOR-δOR HETEROMERIZATION
Localization studies examining heteromerization between δOR
and κ opioid receptors (κOR) found them to be expressed in
the same neuroblastoma cell line (Baumhaker et al., 1993) and
co-expressed in axons of the dorsal horn of the spinal cord
(Wessendorf and Dooyema, 2001). Co-immunoprecipitation
studies using lysates from cells expressing differentially epitope
tagged receptors (Jordan and Devi, 1999) or from peripheral sen-
sory neurons (Berg et al., 2012) show that δOR and κOR form
interacting complexes. That these two receptors are in close prox-
imity for direct receptor-receptor interactions was demonstrated
through the use of bioluminescence resonance energy transfer
assays (BRET) (Ramsay et al., 2002). Signaling studies in cells
co-expressing δOR and κOR show a unique “biochemical finger-
print” in vitro compared to cells expressing individual receptors
(Jordan and Devi, 1999) since they report (i) a decrease in the
binding affinity of δOR or κOR agonists; (ii) an increase in the
binding affinity of a combination of δOR and κOR agonists or
antagonists; (iii) an increase in signaling with a combination of
δOR and κOR agonists; and (iv) that etorphine is not able to inter-
nalize δOR; etorphine internalizes δOR in cells expressing only
this receptor (Jordan and Devi, 1999). However, it is not known
whether this “biochemical fingerprint” observed for δOR-κOR
heteromers in heterologous cells co-expressing epitope-tagged
receptors is also observed in endogenous tissue. Studies with
unique reagents targeting δOR-κOR heteromers show that a biva-
lent ligand, KDN-21, made up of a κOR antagonist, 5′-GNTI,
that is joined by a spacer arm to a δOR antagonist, naltrindole,
exhibits antagonistic activity but has no antinociceptive activity
(Bhushan et al., 2004). Another reagent, 6′-guanidinonaltrindole
(6′-GNTI) was initially identified as a δOR-κOR selective agonist
that exhibits antinociceptive activity when administered intrathe-
cally (i.t.) but not intracerebroventricularly (i.c.v) (Waldhoer
et al., 2005). However, recent studies have reported that 6′-GNTI
exhibits biased agonistic activity for κOR both in heterologous
cells and striatal neurons (Rives et al., 2012; Schmid et al.,
2013). This brings into question the selectivity of this compound
for δOR-κOR heteromers. Finally, a δOR-κOR heteromer selec-
tive antibody has been generated and characterized (Table 1).
Although not much is known about the ability of this antibody
to block heteromer-mediated binding and signaling, it has been
useful in demonstrating a role for δOR-κOR heteromer func-
tion in vivo (Berg et al., 2012). Administration of the δOR-κOR
heteromer selective antibody into the hind paw of rats poten-
tiated the antinociceptive response of a subthreshold dose of
DPDPE such that the latter now gave nearly the maximal possible
antinociceptive response required to inhibit the thermal allody-
nia produced by PGE2 (Berg et al., 2012). Since, treatment with
the κOR antagonist, nor-BNI, also increases the antinociceptive
response of a subthreshold dose of DPDPE although not to the
same extent as the δOR-κOR heteromer selective antibody (Berg
et al., 2012), these results suggest that either drugs targeting the
δOR-κOR heteromer or a combination of the heteromer-selective
antibody with DPDPE would be more effective in the treatment
of thermal allodynia.
δOR-CB1R HETEROMERIZATION
A number of early studies suggested interactions between δOR
and CB1 cannabinoid receptors (CB1R). These included (i)
additive effects on signaling in N18TG neuroblastoma cells
by a combination of opioid and cannabinoid ligands (Shapira
et al., 1998); (ii) release of leucine-enkephalin during 9-THC-
mediated antinociception (Welch and Eads, 1999); (iii) signal
cross-desensitization between CB1R and δOR (Shapira et al.,
1998); (iv) the anxiolytic effects of the CB1R agonist, 9-THC,
could be blocked by the δOR antagonist, naltrindole (Berrendero
and Maldonado, 2002); (v) increases in the levels and activity of
CB1R in some brain regions of δOR knockout mice (Berrendero
et al., 2003); and (vi) increases in δOR activity in CB1R knockout
mice (Uriguen et al., 2005). Co-localization studies demonstrated
the presence of CB1R and δOR in the same neuroblastoma cell
line (Shapira et al., 1998) and within the cell bodies and processes
of primary cortical neurons (Rozenfeld et al., 2012). Moreover,
co-immunoprecipitation studies detect the formation of interact-
ing CB1R-δOR complexes only in cells that co-express both recep-
tors (Rozenfeld et al., 2012) and proximity based assays show that
both receptors are in close proximity for direct receptor-receptor
interactions in live cells (Rios et al., 2006). Examination of unique
signaling showed that the δOR-CB1R heteromer exhibits a dis-
tinct biochemical fingerprint in heterologous cells in that (i) the
presence of δOR or low concentrations of δOR ligands decreases
the signaling potency of a CB1R agonist in heterologous cells and
this is not seen in cells with a knockdown of δOR levels (Rozenfeld
et al., 2012); (ii) the activity of CB1R is increased in cortical mem-
branes from δOR knockout mice (Rozenfeld et al., 2012); (iii) in
the presence of δOR a CB1R agonist activates a pathway involv-
ing phospholipase C (PLC) and β-arrestin2 while in the absence
of δOR it activates Gαi/o-mediated signaling (Rozenfeld et al.,
2012); (iv) in cells co-expressing CB1R and δOR activation of
CB1R leads to accumulation of phosphorylated ERk1/2 in centro-
somes (Rozenfeld et al., 2012); (v) activation of CB1R promotes
increased cell survival only in cells co-expressing CB1R and δOR
(Rozenfeld et al., 2012); and (vi) treatment with a CB1R antag-
onist decreases the survival of primary cortical neurons from
wild-type but not from δOR knockout mice (Rozenfeld et al.,
2012). Additional studies supporting heteromerization between
δOR and CB1R include those examining the maturation and
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trafficking of the two receptors. These studies show that co-
expression of δOR changes the localization of CB1R from an
intracellular compartment to the cell surface and this involves
increased association with the adaptor protein AP-2 (Rozenfeld
et al., 2012) and, reducing δOR levels in F11 cells that co-express
CB1R and δOR leads to a decrease in the surface expression of
CB1R (Rozenfeld et al., 2012).
To date reagents that selectively disrupt the δOR-CB1R het-
eromer or ligands targeting this heteromer have not been devel-
oped. However, antibodies that selectively recognize δOR-CB1R
heteromers have been generated and characterized (Table 1). The
δOR-CB1R heteromer-selective antibody was used to examine
the regulation of the heteromer during neuropathic pain. We
detected changes in heteromer levels 14 days after induction of
neuropathic pain. Specifically, the antibody detected significant
increases in δOR-CB1R heteromer levels in cortex, hypotha-
lamus and midbrain of animals exhibiting neuropathic pain
(Bushlin et al., 2012). This antibody was also useful in deter-
mining the heteromer-selective fingerprint in that it could block
CB1R agonist-mediated increases in δOR activity and this was
seen only in membranes from animals with neuropathic pain
(Bushlin et al., 2012). Taken together, these studies indicate that
the δOR-CB1R heteromer could be a novel therapeutic target
in the treatment of neuropathic pain. Moreover, the δOR-CB1R
heteromer-selective antibody could also be a potential therapeu-
tic for the treatment of neuropathic pain given that it could block
heteromer- mediated signaling.
CB1R-AT1R HETEROMERIZATION
Studies showing an increase in CB1R levels in liver cells that
also express AT1 angiotensin receptors (AT1R) suggested pos-
sible interactions between these receptors (Teixeira-Clerc et al.,
2006; Mallat and Lotersztajn, 2008; Siegmund and Schwabe,
2008; Lanthier et al., 2009). Co-localization of CB1R with AT1R
has been demonstrated in hepatic stellate cells activated in
response to chronic ethanol administration (Rozenfeld et al.,
2011). Furthermore, co-immunoprecipitation studies show that
CB1R and AT1R form interacting complexes in these cells
(Rozenfeld et al., 2011). Examination of the biochemical pro-
file of the CB1R-AT1R heteromer shows that the AT1R agonist
induces a rapid and robust increase in ERK1/2 phosphorylation
via Gαi instead of Gαq in cells co-expressing both receptors, and
this is reduced either by decreasing the levels of CB1R using
siRNA, or by inhibiting the activity of diacylglycerol lipase, the
enzyme involved in the synthesis of the endocannabinoid 2-
arachidonoylglycerol (Rozenfeld et al., 2011). In addition, CB1R
ligands modulate AT1R-mediated increases in ERK1/2 phospho-
rylation with agonists potentiating and antagonists blocking sig-
naling (Rozenfeld et al., 2011). Moreover, in cells co-expressing
CB1R and AT1R phosphorylation of ERK1/2 by a CB1R ago-
nist is only detected in the presence of a very low non-signaling
dose of an AT1R agonist (Rozenfeld et al., 2011). Another inter-
esting feature of cells co-expressing CB1R and AT1R is that
although CB1R activation does not lead to increases in intra-
cellular Ca+2 levels, activation of AT1R induces increases via
Gαq but this requires the presence of CB1R since it is attenu-
ated following siRNA-mediated knockdown of CB1R (Rozenfeld
et al., 2011). Additional support for direct interactions between
CB1R and AT1R comes from studies examining the maturation
of these receptors. These studies show that the expression of AT1R
changes the localization of CB1R from an intracellular compart-
ment to the plasmamembrane in Neuro 2A cells (Rozenfeld et al.,
2011).
Although reagents that selectively disrupt CB1R-AT1R het-
eromers and ligands that selectively target this heteromer
pair have not as yet been generated, antibodies that selec-
tively recognize this heteromer have (Table 1). The CB1R-AT1R
heteromer-selective antibody was used to examine the heteromer
signaling fingerprint. The antibody can block angiotensin II-
mediated ERK1/2 phosphorylation only in cells expressing the
heteromer but not when CB1R levels are reduced in these
cells by siRNA treatment; this indicates that ERK1/2 phos-
phorylation by angiotensin II is mediated via the CB1R-AT1R
heteromer (Rozenfeld et al., 2011). In addition, the antibody
can block the secretion of fibrogenic proteins including α-
SMA from activated hepatic stellate cells obtained from rats
chronically treated with ethanol (Rozenfeld et al., 2011). This
together with observations indicating that the profibrogenic
activity of AT1R in ethanol induced liver fibrosis requires the
presence of CB1R (Rozenfeld et al., 2011) suggest that the
CB1R-AT1R heteromer represents a novel therapeutic target for
the treatment of liver fibrosis and that the CB1R-AT1R het-
eromer by its ability to block the secretion of fibrogenic pro-
teins could potentially be used as a therapeutic to treat liver
fibrosis.
CONCLUSIONS
In this review we describe how a subtractive immunization
strategy can be successfully used to generate monoclonal anti-
bodies that are selective for a given heteromer pair and that
can be useful for examination of endogenous heteromers. Even
though the procedure is time consuming, and requires a num-
ber of controls during screening procedures for determining the
heteromer-selectivity of the antibodies, there are many advan-
tages to developing the heteromer selective antibodies. These
include the fact that they recognize a unique epitope that is
present only in cells/tissues expressing the heteromer of interest,
and thus they could be used to map the targeted heteromer in
endogenous tissue and to monitor changes in heteromer levels
during pathological conditions. In addition, heteromer-selective
antibodies are also useful to discriminate the contribution of the
heteromer from individual receptor homomers for a given signal-
ing response. Finally, in select cases heteromer-selective antibod-
ies have been useful to block a biological response. In this case
the antibodies could be used as therapeutic targets in pathologi-
cal conditions where heteromer levels are upregulated in addition
to being useful in the identification of heteromer-selective/biased
ligands. Thus, heteromer-selective antibodies represent unique
and invaluable tools that would help in our understanding
of the physiological roles of GPCR heteromers in endogenous
tissues.
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